A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms.

European Journal of Clinical Pharmacology
Michela CiniG Palareti

Abstract

Warfarin dosing is affected by clinical and genetic variants, but the contribution of the genotype associated with warfarin resistance in pharmacogenetic algorithms has not been well assessed yet. We developed a new dosing algorithm including polymorphisms associated both with warfarin sensitivity and resistance in the Italian population, and its performance was compared with those of eight previously published algorithms. Clinical and genetic data (CYP2C9*2, CYP2C9*3, VKORC1 -1639 G > A, and VKORC1 3730 G > A) were used to elaborate the new algorithm. Derivation and validation groups comprised 55 (58.2% men, mean age 69 years) and 40 (57.5% men, mean age 70 years) patients, respectively, who were on stable anticoagulation therapy for at least 3 months with different oral anticoagulation therapy (OAT) indications. Performance of the new algorithm, evaluated with mean absolute error (MAE) defined as the absolute value of the difference between observed daily maintenance dose and predicted daily dose, correlation with the observed dose and R(2) value, was comparable with or slightly lower than that obtained using the other algorithms. The new algorithm could correctly assign 53.3%, 50.0%, and 57.1% of patients to the low (≤25 mg/...Continue Reading

References

May 1, 1992·Archives of Internal Medicine·P SmithM Abdelnoor
Jun 27, 1991·The New England Journal of Medicine·J Hirsh
Nov 1, 1994·Annals of Internal Medicine·P S WellsJ Hirsh
Sep 24, 2002·The Annals of Pharmacotherapy·Randall K AbsherMary H Parker
Sep 4, 2007·Journal of Thrombosis and Haemostasis : JTH·M J RiederA E Rettie
Oct 2, 2007·Journal of Thrombosis and Thrombolysis·Brian F Gage, Lawrence J Lesko
Nov 9, 2007·Circulation·Jeffrey L AndersonUNKNOWN Couma-Gen Investigators
Apr 25, 2008·Cardiology·Pål J SmithHarald Arnesen
Jul 4, 2008·Clinical Pharmacology and Therapeutics·H SchellemanS E Kimmel
Aug 30, 2008·Pharmacotherapy·Nita A Limdi, David L Veenstra
Aug 30, 2008·Clinical Pharmacology and Therapeutics·J A PeriniG Suarez-Kurtz
Sep 2, 2008·European Journal of Clinical Pharmacology·Laurent Becquemont
Feb 21, 2009·The New England Journal of Medicine·UNKNOWN International Warfarin Pharmacogenetics ConsortiumJ A Johnson
Apr 9, 2010·Clinical Pharmacology and Therapeutics·P LenziniB F Gage
Apr 21, 2010·Pharmacogenomics·Guang-Ming TanBryan P Yan
May 18, 2010·Current Opinion in Pulmonary Medicine·Alejandro Lazo-Langner, Michael J Kovacs
Mar 2, 2011·The Pharmacogenomics Journal·A PavaniV K Kutala

❮ Previous
Next ❯

Citations

Oct 24, 2012·European Journal of Clinical Pharmacology·Jane SkovJørgen Jespersen
Oct 16, 2012·European Journal of Clinical Pharmacology·Michela CiniGualtiero Palareti
Sep 11, 2013·European Journal of Clinical Pharmacology·Dhakchinamoorthi Krishna KumarChandrasekaran Adithan
Jul 11, 2013·Molecular Diagnosis & Therapy·Sherif M M EkladiousHazem S Abou-Youssef
Aug 31, 2013·PloS One·Cristina MazzaccaraLucia Sacchetti
Jun 19, 2013·Journal of Thrombosis and Thrombolysis·Priccila ZuchinaliLuis E Rohde
Feb 28, 2014·Molecular Diagnosis & Therapy·Mohammad I Saleh, Sameh Alzubiedi
Aug 8, 2013·British Journal of Clinical Pharmacology·Talitha I VerhoefAnke-Hilse Maitland-van der Zee
Dec 19, 2014·European Journal of Clinical Pharmacology·Dhakchinamoorthi Krishna KumarChandrasekaran Adithan
Nov 24, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Aisha QayyumMuhammad Ismail
Jun 18, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Aisha QayyumMuhammad Ismail
Oct 23, 2018·Pharmacogenomics·Aditi ShendreNita A Limdi
Apr 2, 2015·American Journal of Therapeutics·Mohammad I Saleh
Dec 31, 2014·Therapeutic Drug Monitoring·Shamin M SaffianStephen B Duffull
May 9, 2019·Journal of Cardiovascular Pharmacology and Therapeutics·May MakGladys Mitani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Current Opinion in Hematology
Esteban Gandara, Philip S Wells
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Michael P GulsethWilliam E Dager
British Journal of Clinical Pharmacology
Guilherme Suarez-Kurtz
© 2022 Meta ULC. All rights reserved